176 related articles for article (PubMed ID: 32207069)
21. Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach.
Akkineni R; Tapp S; Tosteson AN; Lee A; Miller KL; Choi HK; Zhu Y; Albert DA
J Rheumatol; 2014 Apr; 41(4):739-48. PubMed ID: 24584921
[TBL] [Abstract][Full Text] [Related]
22. Febuxostat--treatment for hyperuricemia and gout?
Moreland LW
N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
[No Abstract] [Full Text] [Related]
23. New therapeutic approach to hyperuricemia and gout in the light of recommendations.
Lioté F
Joint Bone Spine; 2016 Jul; 83(4):376-80. PubMed ID: 27085801
[No Abstract] [Full Text] [Related]
24. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
[TBL] [Abstract][Full Text] [Related]
25. Safety of urate-lowering therapies: managing the risks to gain the benefits.
Keenan RT
Rheum Dis Clin North Am; 2012 Nov; 38(4):663-80. PubMed ID: 23137576
[TBL] [Abstract][Full Text] [Related]
26. Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD.
Sarvepalli PS; Fatima M; Quadri AK; Taher AR; Habeeb A; Amreen F; Parveen BN; Rajaram KG
Saudi J Kidney Dis Transpl; 2018; 29(5):1050-1056. PubMed ID: 30381500
[TBL] [Abstract][Full Text] [Related]
27. Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems.
Hiramitsu S; Ishiguro Y; Matsuyama H; Yamada K; Kato K; Noba M; Uemura A; Matsubara Y; Yoshida S; Kani A; Tokuda M; Kato H; Hasegawa K; Uchiyama T; Matsubara S; Mori K; Kimura H; Shino K; Kato Y; Ishii J
Clin Exp Hypertens; 2014; 36(6):433-40. PubMed ID: 24164405
[TBL] [Abstract][Full Text] [Related]
28. How PCP education can impact gout management: the gout essentials.
Weaver AL; Cheh MA; Kennison RH
J Clin Rheumatol; 2008 Oct; 14(5 Suppl):S42-6. PubMed ID: 18830090
[No Abstract] [Full Text] [Related]
29. Asymptomatic hyperuricemia: is it really asymptomatic?
Yip K; Cohen RE; Pillinger MH
Curr Opin Rheumatol; 2020 Jan; 32(1):71-79. PubMed ID: 31688126
[TBL] [Abstract][Full Text] [Related]
30. [HYPERURICEMIA AND POTENTIAL RISK OF CARDIOVASCULAR AND RENAL DISEASES].
Schils R; Krzesinski JM
Rev Med Liege; 2016 May; 71(5):262-8. PubMed ID: 27337847
[TBL] [Abstract][Full Text] [Related]
31. Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.
Castrejon I; Toledano E; Rosario MP; Loza E; Pérez-Ruiz F; Carmona L
Rheumatol Int; 2015 Jul; 35(7):1127-37. PubMed ID: 25519877
[TBL] [Abstract][Full Text] [Related]
32. Asymptomatic hyperuricemia: to treat or not to treat.
Dincer HE; Dincer AP; Levinson DJ
Cleve Clin J Med; 2002 Aug; 69(8):594, 597, 600-2 passim. PubMed ID: 12184468
[TBL] [Abstract][Full Text] [Related]
33. Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study.
Liu C; Zhao Q; Zhen Y; Gao Y; Tian L; Wang L; Ji L; Liu G; Ji Z; Liu K
Can J Cardiol; 2013 Sep; 29(9):1048-54. PubMed ID: 23395281
[TBL] [Abstract][Full Text] [Related]
34. [Hyperuricemia and gout: diagnosis and therapy].
Tausche AK; Unger S; Richter K; Wunderlich C; Grässler J; Roch B; Schröder HE
Internist (Berl); 2006 May; 47(5):509-20; quiz 521. PubMed ID: 16586130
[TBL] [Abstract][Full Text] [Related]
35. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
[TBL] [Abstract][Full Text] [Related]
36. The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies.
Pontremoli R
Curr Med Res Opin; 2017 Nov; 33(sup3):27-32. PubMed ID: 28952388
[TBL] [Abstract][Full Text] [Related]
37. [Case presentation--tophaceous gout].
Von Zingel M
MMW Fortschr Med; 2012 Apr; 154 Suppl 1():8-9. PubMed ID: 23427363
[No Abstract] [Full Text] [Related]
38. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
39. Allopurinol Against Progression of Chronic Kidney Disease.
Golmohammadi S; Almasi A; Manouchehri M; Omrani HR; Zandkarimi MR
Iran J Kidney Dis; 2017 Jul; 11(4):286-293. PubMed ID: 28794291
[TBL] [Abstract][Full Text] [Related]
40. Febuxostat : a viewpoint by Naomi Schlesinger.
Schlesinger N
Drugs; 2008; 68(13):1875-6. PubMed ID: 18729539
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
